In India, around 40 million individuals have chronically infected with hepatitis B. This infection is in responsible for 70 percent of chronic hepatitis and 80 percent of liver cirrhosis.
The Hepatitis B vaccine has been a part of India’s Universal Immunization Program since 2002. The vaccine is given in three dosages that include one after the first month of the first dose and the second following a half year post the first dose.
Cipla’s hepatitis B vaccine can prevent 95 percent of the recipients from developing up a chronic infection, protecting them for decades. Cipla Ltd, a global pharmaceutical company headquartered in India, has launched an adult hepatitis B vaccine in India.
Serum Institute of India Private Limited (SII) under a co-exclusive agreement, for adults Cipla will market the vaccine while SII will market it for adults and children.
Dr. Umang Vohra, Global CEO Cipla Ltd said, “This agreement will enable Cipla to give affordable vaccines for a chronic disease like hepatitis B. Cipla’s strong marketing network and reach will ensure maximum accessibility of the vaccines in India”.
In India, around 40 million individuals have chronically infected with hepatitis B. This infection is responsible for 70 percent of chronic hepatitis and 80 percent of liver cirrhosis. Hepatitis B is spread through contact with an infected individual’s blood and body liquids.
All who are not vaccinated are at risk of infection. Since 2002, the hepatitis B vaccine has been a piece of India’s Universal Immunization Programme. This vaccine can protect 95 percent of recipients from developing chronic hepatitis B.
The vaccine is given in three doses that include one after the primary month of the first dosage and the second following a half year post the first dose.
The vaccine can protect the recipient from this infection for quite a long time. In addition, it is expected to bring down the number of cases of liver cirrhosis and liver cancer.